Theriva Biologics Inc. Earnings

The next earnings date for Theriva Biologics Inc. has not yet been scheduled.

Analyst Estimates of Theriva Biologics Inc. Earnings

No Results.
Report DateEstimated Earnings Per Share
No Results.

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

Theriva Biologics Inc. Earnings: Historical

Report DateBefore/After MarketEarnings Per ShareSurprise %
05/05/2025Before Market$-1.550.64%
03/24/2025Before Market$-11.49-59.14%
11/11/2024Before Market$-6.81-29.73%
08/13/2024Before Market$-10.75-3,739.29%
05/07/2024Before Market$-0.3011.76%
03/25/2024Before Market$-0.3417.07%
11/13/2023Before Market$-0.1948.65%
08/08/2023Before Market$-0.345.56%
05/11/2023Before Market$-0.306.25%
03/30/2023Before Market$-0.330.00%
11/10/2022After Market$-0.3315.38%
08/11/2022Before Market$-0.3111.43%
05/16/2022Before Market$-0.300.00%
03/16/2022After Market$-0.40-33.33%
11/03/2021After Market$-0.2020.00%
08/05/2021After Market$-0.200.00%
05/05/2021After Market$-1.30-550.00%
03/04/2021After Market$-1.40-75.00%
11/10/2020After Market$-1.4017.65%
08/06/2020After Market$-1.600.00%
05/05/2020After Market$-1.7037.04%
02/20/2020After Market$-1.9017.39%
11/04/2019After Market$-3-30.43%
08/08/2019After Market$-2.204.35%
05/08/2019After Market$-2.204.35%
02/27/2019After Market$-2.8065.43%
11/08/2018After Market$-9.1031.32%
08/08/2018After Market$-11.6017.14%
05/08/2018After Market$-6.5062.86%
02/22/2018Before Market$7142.87%
11/01/2017After Market$-49-223.01%
08/03/2017Before Market$-10.5047.05%
05/04/2017After Market$-772.73%
03/02/2017After Market$-773.68%
11/01/2016Before Market$-31.5013.46%
08/03/2016After Market$-2147.83%
05/05/2016After Market$-427.69%
03/10/2016After Market$-423.23%
11/05/2015After Market$-2834.43%
08/10/2015Before Market$-66.50-72.73%
05/11/2015After Market$-38.50-37.50%
03/16/2015Before Market$-31.50-50.00%
11/14/2014Before Market$-28-60.00%
08/14/2014---$-28-23.08%
05/15/2014---$-24.508.68%
03/31/2014---$-31.50-42.08%
11/14/2013---$-28-39.17%
08/14/2013---$-21-9.09%
04/16/2013---$-119-871.43%
11/20/2012---$-505.87---
08/13/2012---$-496.19---
05/15/2012---$-328.09---
03/30/2012---$-38.50-266.67%
11/14/2011---$-10.5025.00%
08/15/2011---$-527.12---
05/16/2011---$-758.56---
11/15/2010---$-278.76---
08/16/2010---$391.76---
05/18/2010---$-441.35---
03/03/2010---$-457.14---
11/17/2009---$-255.54---
08/14/2009---$-361.30---
05/15/2009---$-467.14---
03/31/2009---$-1442.86%
11/14/2008---$-603.51---
08/14/2008---$-31.5018.18%
05/15/2008---$-52.50-7.14%
03/31/2008---$-80.50-91.67%
11/14/2007---$-420.00%
08/13/2007---$-3516.67%
05/15/2007---$-7,863.65---
03/08/2007---$-7,875---
11/17/2006---$-25.03---
08/16/2006---$-47.55---
05/16/2006---$0---
03/09/2006---$-270.83---
11/18/2005---$-285.03---
08/17/2005---$0---
05/10/2005---$0---
03/10/2005---$0---
11/12/2004---$0---
08/11/2004---$0---
05/11/2004---$0---
11/14/2003---$0---
08/13/2003---$1,000,000.00---
05/13/2003---$-331,168.16---
11/15/2002---$-422,879.94---
08/14/2002---$-836,543.65---
05/01/2002---$-833,481.28---
11/01/2001---$-94.50-80.00%
08/02/2001---$-84-60.00%
11/09/1999---$-52.50-66.67%
03/27/1997---$-199.50-18.75%

More About Theriva Biologics Inc.

Website
https://therivabio.com
Country
USA
Full Time Employees
20

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d'Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.

“Theriva Biologics Inc. Earnings” Can Refer to the Theriva Biologics Inc. Earnings Date

Some people say “Theriva Biologics Inc. earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my Theriva Biologics Inc. position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning Theriva Biologics Inc. Stock on the Earnings Date

If you own Theriva Biologics Inc. stock (TOVX) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Theriva Biologics Inc. might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading Theriva Biologics Inc. shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More Theriva Biologics Inc. Earnings

You can contact us any time if you would like to ask questions about Theriva Biologics Inc. earnings or anything else related to the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.